Jul 28, 2020

TCR² Therapeutics Announces Pricing of Public Offering of Common Stock

Jul 27, 2020

TCR² Therapeutics Announces Proposed Public Offering of Common Stock

Jul 26, 2020

TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors

Jul 24, 2020

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors

Jun 17, 2020

TCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare Conference

May 27, 2020

TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives

May 15, 2020

TCR² Therapeutics to Present Data on PD-1 Switch TRuC Enhancement at American Association for Cancer Research (AACR) Virtual Meeting 2020

May 14, 2020

TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 04, 2020

TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors

Apr 15, 2020

TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors